QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)

Mirum Pharmaceuticals Stock Price, News & Analysis (NASDAQ:MIRM)

$31.70
-0.30 (-0.94%)
(As of 12/4/2023 ET)
Compare
Today's Range
$30.97
$32.31
50-Day Range
$27.14
$32.35
52-Week Range
$17.49
$33.39
Volume
644,779 shs
Average Volume
496,077 shs
Market Capitalization
$1.48 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.78

Mirum Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.13 Rating Score
Upside/​Downside
72.8% Upside
$54.78 Price Target
Short Interest
Bearish
13.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.69
Upright™ Environmental Score
News Sentiment
0.62mentions of Mirum Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth
Growing
From ($2.45) to ($0.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

301st out of 952 stocks

Pharmaceutical Preparations Industry

128th out of 434 stocks


MIRM stock logo

About Mirum Pharmaceuticals Stock (NASDAQ:MIRM)

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

MIRM Stock Price History

MIRM Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Mirum Pharmaceuticals Inc MIRM
11 Analysts Have This to Say About Mirum Pharmaceuticals
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Earnings Outlook For Mirum Pharmaceuticals
Mirum Pharmaceuticals to sell 7.94M shares for holders
See More Headlines
Receive MIRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/13/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MIRM
Fax
N/A
Employees
249
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$54.78
High Stock Price Target
$77.00
Low Stock Price Target
$37.00
Potential Upside/Downside
+72.8%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

Net Income
$-135,660,000.00
Net Margins
-113.45%
Pretax Margin
-112.82%

Debt

Sales & Book Value

Annual Sales
$144.73 million
Book Value
$3.85 per share

Miscellaneous

Free Float
35,399,000
Market Cap
$1.48 billion
Optionable
Not Optionable
Beta
1.21
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Christopher  PeetzMr. Christopher Peetz (Age 44)
    President, CEO & Director
    Comp: $1.09M
  • Mr. Peter Radovich M.B.A. (Age 45)
    Ph.D., Chief Operating Officer
    Comp: $732.15k
  • Dr. Pamela Vig Ph.D. (Age 52)
    Head of R&D
    Comp: $678.2k
  • Ms. Lara Longpre MBA (Age 53)
    MSC, Chief Development Officer
    Comp: $678.2k
  • Mr. Eric H. Bjerkholt M.B.A. (Age 63)
    Chief Financial Officer
  • Andrew McKibben
    Vice President of Investor Relations and Finance
  • Mr. Paul K. Ross
    Chief Compliance Officer
  • Ms. Erin Campany (Age 55)
    Senior Vice President of Human Resources
  • Dr. Ian Clements Ph.D. (Age 54)
    Consultant
    Comp: $649.1k
  • Ms. Vinita P. Kumar
    Senior vice President of Quality














MIRM Stock Analysis - Frequently Asked Questions

Should I buy or sell Mirum Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last twelve months. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MIRM shares.
View MIRM analyst ratings
or view top-rated stocks.

What is Mirum Pharmaceuticals' stock price target for 2024?

8 equities research analysts have issued twelve-month target prices for Mirum Pharmaceuticals' shares. Their MIRM share price targets range from $37.00 to $77.00. On average, they expect the company's stock price to reach $54.78 in the next twelve months. This suggests a possible upside of 72.8% from the stock's current price.
View analysts price targets for MIRM
or view top-rated stocks among Wall Street analysts.

How have MIRM shares performed in 2023?

Mirum Pharmaceuticals' stock was trading at $19.50 on January 1st, 2023. Since then, MIRM shares have increased by 62.6% and is now trading at $31.70.
View the best growth stocks for 2023 here
.

When is Mirum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024.
View our MIRM earnings forecast
.

How were Mirum Pharmaceuticals' earnings last quarter?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) issued its earnings results on Thursday, November, 2nd. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.07. The firm earned $47.73 million during the quarter, compared to analyst estimates of $34.31 million. Mirum Pharmaceuticals had a negative trailing twelve-month return on equity of 79.52% and a negative net margin of 113.45%.

What ETFs hold Mirum Pharmaceuticals' stock?

ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Products ETF (BBP).

What other stocks do shareholders of Mirum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX).

When did Mirum Pharmaceuticals IPO?

(MIRM) raised $75 million in an IPO on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

Who are Mirum Pharmaceuticals' major shareholders?

Mirum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Eventide Asset Management LLC (8.49%), Cadian Capital Management LP (3.08%), Polar Capital Holdings Plc (2.52%), Avidity Partners Management LP (2.45%), Adage Capital Partners GP L.L.C. (1.43%) and William Blair Investment Management LLC (1.14%). Insiders that own company stock include Christopher Peetz, Eric Bjerkholt, Ian Clements, James E Flynn, John A Maurer, Jolanda Howe, Lara Longpre, Michael G Grey, Niall O'donnell, Pamela Vig, Patrick J Heron and Peter Radovich.
View institutional ownership trends
.

How do I buy shares of Mirum Pharmaceuticals?

Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MIRM) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -